{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:58:00Z","timestamp":1769633880579,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Peking University First Hospital Youth Clinical Research Special Fund Project","award":["2019CR08"],"award-info":[{"award-number":["2019CR08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10637-023-01391-2","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:02:33Z","timestamp":1692244953000},"page":"719-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Zhao","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinmo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"1391_CR1","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s12094-015-1436-2","volume":"17","author":"M Benavides","year":"2015","unstructured":"Benavides M, Ant\u00f3n A, Gallego J, G\u00f3mez MA, Jim\u00e9nez-Gordo A, La Casta A et al (2015) Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol 17:982\u2013987. https:\/\/doi.org\/10.1007\/s12094-015-1436-2","journal-title":"Clin Transl Oncol"},{"key":"1391_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/clep.S37357","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA (2014) Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 6:99\u2013109. https:\/\/doi.org\/10.2147\/clep.S37357","journal-title":"Clin Epidemiol"},{"key":"1391_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"1391_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB et al (2019) Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 71:104\u2013114. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.013","journal-title":"J Hepatol"},{"key":"1391_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","volume":"16","author":"SKR Mukkamalla","year":"2018","unstructured":"Mukkamalla SKR, Naseri HM, Kim BM, Katz SC, Armenio VA (2018) Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States. J Natl Compr Canc Netw 16:370\u2013376. https:\/\/doi.org\/10.6004\/jnccn.2017.7056","journal-title":"J Natl Compr Canc Netw"},{"key":"1391_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jjco\/hyy082","volume":"48","author":"C Morizane","year":"2018","unstructured":"Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J (2018) New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol 48:703\u2013711. https:\/\/doi.org\/10.1093\/jjco\/hyy082","journal-title":"Jpn J Clin Oncol"},{"key":"1391_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"1391_CR8","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A et al (2020) Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 147:2190\u20132198. https:\/\/doi.org\/10.1002\/ijc.33013","journal-title":"Int J Cancer"},{"key":"1391_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cncr.34541","volume":"129","author":"KC Ohaegbulam","year":"2023","unstructured":"Ohaegbulam KC, Koethe Y, Fung A, Mayo SC, Grossberg AJ, Chen EY et al (2023) The multidisciplinary management of cholangiocarcinoma. Cancer 129:184\u2013214. https:\/\/doi.org\/10.1002\/cncr.34541","journal-title":"Cancer"},{"key":"1391_CR10","doi-asserted-by":"publisher","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European J Cancer (Oxford, England : 1990) 54:139-148. https:\/\/doi.org\/10.1002\/cncr.34541","DOI":"10.1002\/cncr.34541"},{"key":"1391_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/cncr.34541","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238. https:\/\/doi.org\/10.1002\/cncr.34541","journal-title":"Ann Oncol"},{"key":"1391_CR12","doi-asserted-by":"publisher","unstructured":"De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D (2020) Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep Innov Hepatol 2:100170. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100170","DOI":"10.1016\/j.jhepr.2020.100170"},{"key":"1391_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK et al (2022) Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020","journal-title":"J Natl Compr Canc Netw"},{"key":"1391_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671\u2013672. https:\/\/doi.org\/10.1093\/annonc\/mdw649","journal-title":"Ann Oncol"},{"key":"1391_CR15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/jgh.14889","volume":"35","author":"K Sawada","year":"2020","unstructured":"Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T (2020) Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. Journal of gastroenterology and hepatology 35:1042\u20131048. https:\/\/doi.org\/10.1111\/jgh.14889","journal-title":"Journal of gastroenterology and hepatology"},{"key":"1391_CR16","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Aithal GP, Bjornsson ES et al (2019) EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 70:1222\u20131261. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"1391_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-017-0298-2","volume":"5","author":"ZJ Brown","year":"2017","unstructured":"Brown ZJ, Heinrich B, Steinberg SM, Yu SJ, Greten TF (2017) Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. Journal for immunotherapy of cancer 5:93. https:\/\/doi.org\/10.1186\/s40425-017-0298-2","journal-title":"Journal for immunotherapy of cancer"},{"key":"1391_CR18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","volume":"23","author":"K Reynolds","year":"2018","unstructured":"Reynolds K, Thomas M, Dougan M (2018) Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist 23:991\u2013997. https:\/\/doi.org\/10.1634\/theoncologist.2018-0174","journal-title":"Oncologist"},{"key":"1391_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature reviews Clinical oncology 13:473\u2013486. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58","journal-title":"Nature reviews Clinical oncology"},{"key":"1391_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.32215","volume":"75","author":"M Li","year":"2022","unstructured":"Li M, Wong D, Vogel AS, Sack JS, Rahma OE, Hodi FS et al (2022) Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology (Baltimore, Md) 75:531\u2013540. https:\/\/doi.org\/10.1002\/hep.32215","journal-title":"Hepatology (Baltimore, Md)"},{"key":"1391_CR21","doi-asserted-by":"publisher","unstructured":"Ueno M, Takabatake H, Hata A, Kayahara T, Morimoto Y, Notohara K et al (2022) Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. Cancer Rep (Hoboken, NJ) 5:e1624. https:\/\/doi.org\/10.1002\/cnr2.1624","DOI":"10.1002\/cnr2.1624"},{"key":"1391_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"1391_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ et al (2011) The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (Baltimore, Md) 54:931\u2013939. https:\/\/doi.org\/10.1002\/hep.24481","journal-title":"Hepatology (Baltimore, Md)"},{"key":"1391_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00000658-199610000-00005","volume":"224","author":"A Nakeeb","year":"1996","unstructured":"Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S et al (1996) Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224:463\u2013473. https:\/\/doi.org\/10.1097\/00000658-199610000-00005","journal-title":"Ann Surg"},{"key":"1391_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529\u2013536. https:\/\/doi.org\/10.1007\/s10637-017-0453-0","journal-title":"Invest New Drugs"},{"key":"1391_CR26","doi-asserted-by":"publisher","unstructured":"Okuno T, Nakashima K, Mitarai Y, Kataoka M, Tobita H, Nagase M et al (2022) Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. Respiratory Med Case Rep 40:101773. https:\/\/doi.org\/10.1016\/j.rmcr.2022.101773","DOI":"10.1016\/j.rmcr.2022.101773"},{"key":"1391_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2214\/ajr.181.3.1810819","volume":"181","author":"JH Lim","year":"2003","unstructured":"Lim JH (2003) Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol 181:819\u2013827. https:\/\/doi.org\/10.2214\/ajr.181.3.1810819","journal-title":"AJR Am J Roentgenol"},{"key":"1391_CR28","doi-asserted-by":"publisher","unstructured":"Granata V, Fusco R, Catalano O, Avallone A, Palaia R, Botti G et al (2017) Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases. PLoS One 12:e0179951. https:\/\/doi.org\/10.1371\/journal.pone.0179951","DOI":"10.1371\/journal.pone.0179951"},{"key":"1391_CR29","doi-asserted-by":"publisher","unstructured":"Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV et al (2017) Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2:e000268. https:\/\/doi.org\/10.1136\/esmoopen-2017-000268","DOI":"10.1136\/esmoopen-2017-000268"},{"key":"1391_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H et al (2020) Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World journal of gastroenterology 26:353\u2013365. https:\/\/doi.org\/10.3748\/wjg.v26.i3.353","journal-title":"World journal of gastroenterology"},{"key":"1391_CR31","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/meg.0000000000002280","volume":"33","author":"B Pi","year":"2021","unstructured":"Pi B, Wang J, Tong Y, Yang Q, Lv F, Yu Y (2021) Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol 33:e858\u2013e867. https:\/\/doi.org\/10.1097\/meg.0000000000002280","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1391_CR32","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.2169\/internalmedicine.2591-18","volume":"58","author":"K Kurokawa","year":"2019","unstructured":"Kurokawa K, Hara M, Iwakami SI, Genda T, Iwakami N, Miyashita Y et al (2019) Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. Intern Med 58:3283\u20133287. https:\/\/doi.org\/10.2169\/internalmedicine.2591-18","journal-title":"Intern Med"},{"key":"1391_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13256-020-02541-3","volume":"14","author":"S Onishi","year":"2020","unstructured":"Onishi S, Tajika M, Bando H, Matsubara Y, Hosoda W, Muro K et al (2020) Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report. J Med Case Rep 14:230. https:\/\/doi.org\/10.1186\/s13256-020-02541-3","journal-title":"J Med Case Rep"},{"key":"1391_CR34","doi-asserted-by":"publisher","unstructured":"Hountondji L, Ferreira De Matos C, Leboss\u00e9 F, Quantin X, Lesage C, Palassin P et al (2023) Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep Innov Hepatol 5:100719. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100719","DOI":"10.1016\/j.jhepr.2023.100719"},{"key":"1391_CR35","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers U, Trauner M, Jansen P, Poupon R (2015) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62:S25-37. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.023","journal-title":"J Hepatol"},{"key":"1391_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1042\/cs20110184","volume":"121","author":"MG Roma","year":"2011","unstructured":"Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, S\u00e1nchez Pozzi EJ (2011) Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 121:523\u2013544. https:\/\/doi.org\/10.1042\/cs20110184","journal-title":"Clin Sci (Lond)"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01391-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:04:05Z","timestamp":1696676645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01391-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01391-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Peking University First Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Is not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Is not needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}